These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 34565287)

  • 1. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
    Wang S; Sun L
    Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.
    Maxwell SA; Cherry EM; Bayless KJ
    Leuk Lymphoma; 2011 May; 52(5):849-64. PubMed ID: 21323512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
    Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
    Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
    Maxwell SA; Li Z; Jaya D; Ballard S; Ferrell J; Fu H
    J Biol Chem; 2009 Aug; 284(33):22379-22389. PubMed ID: 19525224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods.
    Liu Y; Zeng L; Zhang S; Zeng S; Huang J; Tang Y; Zhong M
    Med Oncol; 2013 Jun; 30(2):528. PubMed ID: 23504336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
    Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic analysis of neutrophil apoptosis induced by diffuse large B-cell lymphoma unveils a potential role in neutropenia.
    Jeon BE; Lee JE; Park J; Jung H; Park EG; Lee DH; Seo YS; Kim HS; Shin HJ; Kim SW
    Genes Genomics; 2023 Aug; 45(8):1013-1024. PubMed ID: 37266765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
    Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
    Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.
    Bai H; Wei J; Deng C; Yang X; Wang C; Xu R
    Int J Hematol; 2013 Feb; 97(2):223-31. PubMed ID: 23275230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
    Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
    Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
    Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-MYC-activated lncRNA SNHG20 accelerates the proliferation of diffuse large B cell lymphoma via USP14-mediated deubiquitination of β-catenin.
    Wang C; Fu W; Zhang Y; Hu X; Xu Q; Tong X
    Biol Direct; 2024 Jun; 19(1):47. PubMed ID: 38886753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma.
    Ge X; Lv X; Feng L; Liu X; Gao J; Chen N; Wang X
    PLoS One; 2012; 7(6):e39449. PubMed ID: 22768080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
    Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
    Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.